Intuitive Surgical, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; comparisons are with Q1 2022 unless otherwise noted. Intuitive develops, manufactures, and markets da Vinci surgical systems and the Ion endoluminal system, along with related instruments, accessories, and services. Figures below are in U.S. dollars.
Financial and operating performance
| Metric | Q1 2023 | Q1 2022 | Change / context |
|---|---|---|---|
| Total revenue | $1.696 billion | $1.488 billion | Up 14% |
| Instruments and accessories revenue | $986 million | $810 million | Up 22%; driven mainly by procedure growth |
| Systems revenue | $427 million | $428 million | Essentially flat |
| Service revenue | $283 million | $249 million | Up 14% |
| Gross profit / margin | $1.113 billion / 65.6% | $1.010 billion / 67.9% | Margin down 2.3 percentage points |
| Operating income / margin | $388 million / 22.9% | $408 million / 27.4% | Operating income down 5% |
| Net income attributable to Intuitive | $355 million | $366 million | Down 3%; diluted EPS was $1.00 in both periods |
| Operating cash flow | $371 million | $223 million | Up $148 million |
Revenue growth reflected approximately 26% growth in da Vinci procedures and a larger installed base supporting recurring instruments and service revenue. Recurring revenue, including operating lease revenue, was $1.381 billion, or 81% of revenue, versus $1.143 billion, or 77%, a year earlier. Da Vinci placements were 312, versus 311; the installed base was approximately 7,779, up 12% year over year. Ion procedures increased 162% to approximately 10,200, and its installed base reached approximately 376 systems.
Profitability was pressured by lower product margins, including higher scrap costs and inventory reserves, component and labor costs, foreign exchange effects, and lower da Vinci system average selling prices. SG&A rose 23% to $481 million and R&D rose 16% to $245 million. Interest and other income improved to $34 million from an expense of $6 million, contributing to higher pretax income despite lower operating income. The effective tax rate increased to 14.5% from 8.2%, primarily reflecting lower excess tax benefits from employee equity plans.
Balance sheet, cash flow, and capital allocation
At March 31, cash and cash equivalents were $2.143 billion, short-term investments $2.549 billion, and long-term investments $1.886 billion—$6.579 billion combined, down approximately $163 million from year-end. Current assets were $6.877 billion and current liabilities $1.307 billion. Total liabilities were $1.759 billion; the balance sheet reports no borrowings or debt balance. Stockholders’ equity totaled $11.294 billion.
Operating cash flow was $371 million. Investing activities provided $573 million, principally as investment maturities exceeded purchases, partly offset by $194 million of capital expenditures. Financing activities used $381 million, including $350 million for repurchases of 1.5 million shares and $130 million in taxes on net share settlements of equity awards. The company had approximately $1.1 billion remaining under its repurchase authorization. It expects 2023 capital expenditures of $800 million to $1 billion, more than half for facilities.
Available-for-sale debt securities had $150 million of gross unrealized losses at quarter-end, attributed primarily to higher interest rates. The company said it did not intend, and was not more likely than not required, to sell these securities before recovery of amortized cost.
Outlook, commentary, risks, and contingencies
Management provided no specific revenue or earnings guidance in the filing. It expects substantial R&D investment to continue increasing and capital expenditures to rise to $800 million–$1 billion in 2023. Management stated that cash, cash equivalents, and investments, together with expected operating income, should meet liquidity needs for the foreseeable future.
Management reported approximately 26% da Vinci procedure growth, but noted that Q1 comparisons were affected by pandemic-related disruption in the prior-year quarter. China procedures were affected by COVID-19 in January 2023 and recovered as infections and hospitalizations eased in February and March. Hospital staffing and financial pressures, inflation, higher interest rates, and a softening U.S. capital pipeline are expected to make customers cautious about capital spending; management expects capital demand, particularly in the U.S., to remain affected while conditions are challenging. System placements were flat year over year, and management cited supply-chain, competitive, trade-in, reimbursement, regulatory, and market-acceptance factors that may affect future placements.
Risks include continued shortages and higher costs for semiconductors and other components, reliance on sole- or single-source suppliers, hospital spending constraints, foreign exchange and investment-market volatility, labor availability, and possible disruption from COVID-19 or geopolitical events. The company also highlighted cybersecurity and IT risks. It reported no direct borrowing or deposit exposure to SVB or other directly impacted institutions and no resulting impact to liquidity or operations, but noted that most cash deposits exceed insured limits.
Legal matters include product-liability claims, with several trials scheduled within the next 12 months; the company says it cannot estimate potential losses beyond recognized amounts. In patent litigation, a jury awarded Rex Medical $10 million, which Intuitive intends to appeal; the company does not believe the loss is material. Ethicon litigation includes an appeal concerning SureForm products; an adverse result could restrict imports or require workarounds. The company also faces antitrust litigation relating to instrument service and repair and says it cannot reasonably estimate potential losses in those matters.
Important facts for investors to verify
- Whether procedure growth translates into durable recurring revenue and continued system utilization, especially as pandemic-related comparisons normalize.
- Whether product gross margins recover from Q1 pressure, and how pricing, system mix, foreign exchange, component costs, and inventory reserves affect margins.
- Whether hospital capital constraints and the softer U.S. pipeline weigh on placements, and how the higher share of lease placements affects reported systems revenue and cash generation.
- Progress on the planned $800 million–$1 billion of 2023 capital expenditures and the effects on liquidity and operating cash flow.
- Developments in supplier availability, hospital finances, cybersecurity, investment values, and the legal proceedings and regulatory matters described in the filing.